>>13371281Observation of short-term safety also calls some questioning
In Pfizer's case, there are 371 individuals who have been excluded from the statistical analysis on or prior to 7 days after second injection. No reports have been given about disease course for these individuals. Instead of excluding them, this would have given insight as to ADE risks and risks before vaccine effect is fully active
The imbalance in these 371 excluded individuals 311 in the vaccine group and 60 in the placebo group calls for further questioning. This questioning becomes all more pressing as reports seem to indicate that such unexplained imbalance with higher levels of infections immediately after vaccination. This imbalance should have been investigated to ensure absence of an increased susceptibility risk after vaccination.
Excluded populations such as those with history of covid, immunocompromised, those with immunosuppressive therapies leaves us without clinical trial to validate responsibly benefit/risk
There is no data as to risks to if and when immunity starts to weaken in presence or absence of virus encounter
Significant adverse effects (fever in 16% of the young) comparable to those of the disease itself in younger healthy individuals have been observed. Israel mortality analysis including that of age 15-44 needs to be made public to understand better. Jansen's safety analysis relies on a relatively small sample 3356 individuals.
